Parma (Italy), December 5, 2022 - Following the recent statements appeared in the media, Chiesi Farmaceutici would like to reiterate that the Company is not involved in the events concerning the company Holostem Terapie Avanzate s.r.l. ("Holostem").

The investments in support of Holostem have been carried out directly by Valline Holding s.r.l., without any direct participation of Chiesi Farmaceutici. The position of Valline Holding s.r.l. is clarified in a separate statement.
 

Chiesi Farmaceutici researches, develops and markets innovative drugs in three specific areas: AIR (products and services in the respiratory field, from newborns to adults), RARE (innovative solutions and personalised services to improve the quality of life of patients with rare and ultra-rare diseases) and CARE (products and services to support specialist care and personal care and wellbeing).


Chiesi Farmaceutici strongly reaffirms its commitment and dedication to the development and commercialisation of products in the field of rare diseases through Chiesi Global Rare Diseases, a business unit of the company currently working in the areas of lysosomal storage diseases and haematological disorders. This commitment is confirmed by the recent creation of the Biotech Centre of Excellence in Parma, mainly dedicated to the development and production of biological drugs, such as enzymes, proteins and monoclonal antibodies. Chiesi Farmaceutici is not engaged, nor is it involved, in regenerative or cellular therapies.